Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
Perspectum and ProPath partner on providing clinical trial expertise
Perspectum and ProPath have collaborated to enable pharmaceutical companies running clinical trials for liver disease to receive pathology and imaging expertise from one contract research organisation (CRO).
Synlogic terminates development of ammonia lowering drug
Synlogic has announced plans to suspend the clinical development of SYNB1020 following negative results from the candidate’s Phase Ib/IIa clinical trial in hyperammonemia patients.
Group K Diagnostics and Health Network agree to start clinical trials
Biotechnology firm Group K Diagnostics (GKD) and laboratory medicine services provider Health Network Laboratories (HNL) have partnered on a clinical trial agreement to bring improved clinical experiences to patients and caregivers.
Farxiga meets primary goal in Phase III heart failure trial
AstraZeneca’s Farxiga (dapagliflozin) has met the primary endpoint in Phase III DAPA-HF study involving patients with reduced ejection fraction (HFrEF), with or without type 2 diabetes.
Mallinckrodt begins enrolment in Phase IIa study for liver cirrhosis
Mallinckrodt has started patient recruitment in a Phase IIa clinical trial of MNK-6106 (L-ornithine phenylacetate) for the treatment of hepatic (liver) cirrhosis and hepatic encephalopathy (HE).
Daiichi Sankyo reports positive data from hypercholesterolemia study
Daiichi Sankyo has reported findings from the Phase III clinical trial of bempedoic acid / ezetimibe fixed-dose combination (FDC) tablet in hypercholesterolemia patients.
Baqsimi (glucagon) for the Treatment of Severe Hypoglycaemia
Baqsimi™ (glucagon) is the first nasally administered antihypoglycemic agent indicated for the treatment of severe hypoglycaemia in diabetes patients aged four years and above.
Sanofi reports top-line results for diabetes drug Zynquista
Sanofi has announced top-line data from three Phase III clinical trials performed to assess Zynquista (sotagliflozin) in adults with type 2 diabetes.
Alberta Diabetes Institute to lead new anti-obesity drug study
The Alberta Diabetes Institute (ADI) at the University of Alberta is set to lead a clinical trial of new drug setmelanotide for the treatment of obesity associated with rare genetic disorders in Canada.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.